JP2007063177A - Composition for oral intake intended for lustrous skin - Google Patents

Composition for oral intake intended for lustrous skin Download PDF

Info

Publication number
JP2007063177A
JP2007063177A JP2005250453A JP2005250453A JP2007063177A JP 2007063177 A JP2007063177 A JP 2007063177A JP 2005250453 A JP2005250453 A JP 2005250453A JP 2005250453 A JP2005250453 A JP 2005250453A JP 2007063177 A JP2007063177 A JP 2007063177A
Authority
JP
Japan
Prior art keywords
skin
composition
ascorbic acid
hyaluronic acid
ascorbic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005250453A
Other languages
Japanese (ja)
Other versions
JP4982718B2 (en
Inventor
Shigeharu Fukuda
Toshio Miyake
俊雄 三宅
恵温 福田
Original Assignee
Hayashibara Biochem Lab Inc
株式会社林原生物化学研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hayashibara Biochem Lab Inc, 株式会社林原生物化学研究所 filed Critical Hayashibara Biochem Lab Inc
Priority to JP2005250453A priority Critical patent/JP4982718B2/en
Publication of JP2007063177A publication Critical patent/JP2007063177A/en
Application granted granted Critical
Publication of JP4982718B2 publication Critical patent/JP4982718B2/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

Abstract

PROBLEM TO BE SOLVED: To provide a composition for oral intake which is capable of attaining ameliorating skin flabbiness, wrinkles and/or fine wrinkles and rough skin and improving skin moisture.
SOLUTION: The composition for oral intake is such that the compounding mass ratio of hyaluronic acid to an L-ascorbic acid compound on an L-ascorbic acid basis is (1:4) to (4:1).
COPYRIGHT: (C)2007,JPO&INPIT

Description

本発明は、肌の弛み、シワ及び/又はコジワを改善する美肌用の経口摂取用組成物に関する。 The present invention, skin slackness of about wrinkles and / or oral ingestion composition for beautiful skin to improve fine lines.

従来から、肌の弛み、シワ及びコジワを改善し、美しい肌を保つことは多くの人々が希望とするところであり、これらを目的とする種々の製品が開発されている。 Conventionally, skin looseness of, and improve the wrinkles and fine lines, to keep the beautiful skin is a place where many people and hope, a variety of products for these purposes have been developed. これらの製品は、一般には化粧品という形態で提供され皮膚に塗布されるものが多いが、他方においては経口的に摂取されることにより上記目的を達成しようとする製品もある。 These products are generally although many of them are applied to the skin is provided in the form of cosmetics, there is also a product to be achieved the above object by being ingested orally in the other.

ヒアルロン酸は、真皮層に多く存在し、皮膚の保湿性や弾力性に関与していることが知られている。 Hyaluronic acid is abundantly present in the dermis layer, it is known to be involved in moisture retention and elasticity of the skin. そのため、皮膚の保湿性や弾力性の維持を目的にした、ヒアルロン酸を含有させた食品が幾つか開発されている(特許文献1、特許文献2参照)。 Therefore, the maintenance of moisture and elasticity of the skin and the purpose, food which contains the hyaluronic acid are several developed (Patent Document 1, Patent Document 2).

L−アスコルビン酸類は、皮膚や粘膜の健康維持を助ける抗酸化ビタミンとして、或いは、抗酸化剤として経口摂取用の組成物に利用されている(特許文献3)。 L- ascorbic acids as antioxidant vitamins to help maintain healthy skin and mucous membranes, or are utilized in compositions for oral ingestion as an antioxidant (Patent Document 3). また、L−アスコルビン酸類は、メラニンの生成を抑制することから、美白用の化粧料にも使用されている(特許文献4)。 Also, L- ascorbic acids, since suppressing the formation of melanin, have also been used in cosmetics for whitening (patent document 4). また、L−アスコルビン酸類を利用した、コラーゲン産生増強用の組成物も提案されている(特許文献5)。 Also, L- ascorbic acids using, also composition for enhancing collagen production has been proposed (Patent Document 5). しながら、特定の割合で、ヒアルロン酸とL−アスコルビン酸類とを経口的に摂取することにより、肌の弛み、シワ及び/又はコジワを改善する美肌効果が顕著に発揮されることについての報告はない。 While, at a specific ratio, by ingesting the hyaluronic acid and L- ascorbic acids orally, reports of the skin slackness of beautiful skin effect of improving wrinkles and / or fine lines is remarkably exhibited Absent.

特開平10−165138号公報 JP 10-165138 discloses 特開2005−80532号公報 JP 2005-80532 JP 特開2003−339353号公報 JP 2003-339353 JP 特開平3−139288号公報 JP-3-139288 discloses

本発明は、肌の弛み、シワ及び/又はコジワを改善し、肌荒れの改善や肌のうるおいの向上を達成することができる経口摂取用の組成物を提供することを課題とする。 The present invention, skin slackness of improving wrinkles and / or fine lines, and to provide a composition for oral ingestion that can achieve improved moisture of rough skin improvement and skin.

本発明者は、上記課題を解決するために、鋭意研究した結果、特定の割合でヒアルロン酸およびL−アスコルビン酸類を併せて経口的に摂取すると、効果的に美しい肌を保つことができることを見出し、本発明を完成した。 The present inventors, in order to solve the above problems, intensive studies and as a result, when taken orally together hyaluronic acid and L- ascorbic acids in a specific ratio, found that it is possible to keep the effective beautiful skin Thus, the present invention has been completed. すなわち、本発明は、ヒアルロン酸とL−アスコルビン酸に換算したときのL−アスコルビン酸類との配合割合が、質量比で1:4乃至4:1である経口摂取用組成物を提供することにより上記課題を解決するものである。 That is, the present invention, the mixing ratio of the L- ascorbic acid when converted into hyaluronic acid and L- ascorbic acid, 1 weight ratio: 4 to 4: by providing an oral ingestible composition is a 1 it is intended to solve the above problems.

本発明の経口摂取用組成物は経口摂取することにより、摂取した者の、肌の弛み、シワ及び/又はコジワを改善すると共に、角層のバリア機能を改善し、皮膚の保水力を高め、肌荒れの改善、肌のうるおいが向上し、美しい肌が保持される。 Oral intake composition of the present invention is by ingesting oral, ingested person, skin slack, while improving wrinkles and / or fine lines, improving barrier function of the stratum corneum, increases the water-holding capacity of the skin, improvement of skin roughness, moisture of the skin is improved, beautiful skin is held.

本発明の経口摂取用組成物に使用するヒアルロン酸は、化学合成されたものでもよく、発酵法で製造したものや、動物の組織や微生物等から抽出したものであっても良い。 Hyaluronic acid used in the ingestible compositions of the present invention may be one which is chemically synthesized, and those produced by fermentation, or may be extracted from animal tissues and microorganisms. ヒアルロン酸は、本発明の効果を妨げない限り、必ずしも精製または単離されたものを用いる必要はなく、未分離組成物としての形態、それらを部分精製、或いは、高度に精製したものであってもよい。 Hyaluronic acid, as long as not impairing the effects of the present invention, it is not always necessary to use those purified or isolated, form as unseparated compositions, their partially purified, or be one highly purified it may be. また、本発明の経口摂取用組成物に含まれるヒアルロン酸は、その少なくとも一部がヒアルロン酸ナトリウムなどの塩の形態になっていてもよい。 Moreover, hyaluronic acid contained in the ingestible compositions of the present invention, at least a part may be in the form of a salt such as sodium hyaluronate.

本発明の経口摂取用組成物に含まれるヒアルロン酸の含有量は、特に制限はなく、通常は、該組成物全質量に対して0.1質量%乃至25質量%であることが好ましい。 The content of hyaluronic acid contained in the ingestible compositions of the present invention is not particularly limited, usually, it is preferably 0.1 wt% to 25 wt% relative to the total weight the composition.

本発明で使用するL−アスコルビン酸類としては、経口摂取が可能で、生体内において、ビタミンCとしての生理機能を発揮できるものであれば、特に限定されない。 The L- ascorbic acids for use in the present invention, can be oral ingestion, in vivo, as long as it can exhibit the physiological function as vitamin C, it is not particularly limited. 具体的には、例えば、L−アスコルビン酸や、L−アスコルビン酸配糖体、L−アスコルビン酸脂肪酸エステル、L−アスコルビン酸リン酸エステルなどのL−アスコルビン酸の誘導体、ニコチン酸アミド−Lアスコルビン酸複合体、これらL−アスコルビン酸類のアルカリ金属塩又はアルカリ土類金属塩の他、アンモニウム塩、アミノ酸塩等の塩も同様に使用することができる。 Specifically, for example, L- ascorbic acid and, L- ascorbic acid glycosides, L- ascorbic acid fatty acid esters, derivatives of L- ascorbic acid such as L- ascorbic acid phosphoric acid ester, nicotinic acid amide -L-ascorbic acid complex, these L- ascorbic acids other alkali metal or alkaline earth metal salts of, can be ammonium salts, salts of such amino acid salts used as well. なかでも、L−アスコルビン酸配糖体の1種であるL−アスコルビン酸2−グルコシドは、経口摂取用組成物に配合しても安定であるばかりでなく、経口摂取すると、生体内で徐々に分解されて、持続的にビタミンC作用を発揮し、ヒアルロン酸と組み合わせた場合には、他のL−アスコルビン酸類に比して、強い美肌作用を持続することができるので、特に望ましい。 Of these, L- 1 or a is L- ascorbic acid 2-glucoside ascorbate glycosides are not only stable be formulated for oral intake composition, when orally ingested, gradually in vivo is decomposed, continuously exert vitamin C activity, when combined with hyaluronic acid, in comparison to other L- ascorbic acids, it is possible to sustain a strong skin-beautifying action, particularly desirable.

本発明の経口摂取用組成物に含まれるL−アスコルビン酸類の含有量は、特に制限はなく、通常は、L−アスコルビン酸に換算して、該組成物全質量に対して0.1質量%乃至25質量%であることが好ましい。 The content of L- ascorbic acids contained in ingestible compositions of the present invention is not particularly limited, usually, in terms of L- ascorbic acid, 0.1% by weight relative to the total weight the composition to is preferably 25% by mass.

本発明の経口摂取用組成物におけるヒアルロン酸とL−アスコルビン酸類との配合割合は、本発明の所期の作用効果が達成できればよく、ヒアルロン酸とL−アスコルビン酸に換算したときのL−アスコルビン酸類との配合割合が、質量比で1:4乃至4:1、望ましくは1:2乃至2:1のものが、美肌効果の点で優れている。 The mixing ratio of hyaluronic acid and L- ascorbic acid in orally ingestible composition of the present invention, as long achieved the intended effects of the present invention, L- ascorbic when converted into hyaluronic acid and L- ascorbic acid mixing ratio of the acids is 1 mass ratio: 4 to 4: 1, preferably 1: 2 to 2: 1 things, is superior in skin-beautifying effect.

また、このヒアルロン酸とL−アスコルビン酸類との経口摂取は、これらの2成分を含む組成物を摂取することが望ましいが、ヒアルロン酸とL−アスコルビン酸に換算したときのL−アスコルビン酸類との摂取割合が、質量比で1:4乃至4:1となるように、各々の成分を、別々に経口摂取する場合も、本発明に含まれる。 Furthermore, oral ingestion of the hyaluronic acid with L- ascorbic acids, it is desirable to ingest a composition comprising these two components, the L- ascorbic acid when converted into hyaluronic acid and L- ascorbic acid intake ratio, 1 mass ratio: 4 to 4: to be 1, even if each of the components separately ingested, are included in the present invention.

本発明の経口摂取物組成物の成人1日当たりの摂取量は、所期の作用効果が達成できる限り、特に制限はないが、通常は、ヒアルロン酸の摂取量及びL−アスコルビン酸に換算したときのL−アスコルビン酸類の摂取量は、何れも、1日当たり60mg以上とするのが望ましく、90mg以上が好適であり、120mg以上とするのが特に望ましい。 Intake per day for an adult orally ingestible compositions of the present invention, when long as desired effect can be achieved, is not particularly limited, usually, in terms of intake and L- ascorbic acid hyaluronic acid intake Roh L- ascorbic acids are both is desirable to 1 day 60mg or more, preferably more than 90 mg, to not less than 120mg and particularly desirable.

本発明の経口摂取用組成物は、本発明の作用効果を妨げない範囲で、ヒアルロン酸及びL−アスコルビン酸類以外の、通常経口摂取用組成物に加えられる成分を任意に含有させることができる。 Oral intake composition of the present invention, within a range which does not impair the effects of the present invention, other than hyaluronic acid and L- ascorbic acids, the components added to the normal oral ingestible composition can be arbitrarily contained. 例えば、ブドウ糖、果糖、グルコサミン、ラクトース、蔗糖、α,α−トレハロース、α,β−トレハロース、β,β−トレハロース、ラクトスクロース、マルトオリゴ糖、水飴などの糖類、サイクロデキストリンや同じ出願人による国際公開WO 02/10361号明細書などに記載のサイクロ{→6)−α−D−グルコピラノシル−(1→3)−α−D−グルコピラノシル−(1→6)−α−D−グルコピラノシル−(1→3)−α−D−グルコピラノシル−(1→}の構造を有する環状四糖、或いは、特開2005−95148号公報(特願2004−174880号明細書)などに記載のサイクロ{→6)−α−D−グルコピラノシル−(1→4)−α−D−グルコピラノシル−(1→6)−α−D−グルコピラノシル−(1→4)−α−D For example, glucose, fructose, glucosamine, lactose, sucrose, alpha, alpha-trehalose, alpha, beta-trehalose, beta, beta-trehalose, lactosucrose, maltooligosaccharides, saccharide such as starch syrup, International Publication by cyclodextrin or the same applicant WO cyclo described like 02/10361 Pat {→ 6) -α-D- glucopyranosyl - (1 → 3) -α-D- glucopyranosyl - (1 → 6) -α-D- glucopyranosyl - (1 → 3)-.alpha.-D-glucopyranosyl - (cyclotetrasaccharide having a structure of 1 →}, or JP 2005-95148 JP (Japanese Patent Application No. 2004-174880 specification) cyclo {→ 6 according to such) - alpha-D-glucopyranosyl - (1 → 4) -α-D- glucopyranosyl - (1 → 6) -α-D- glucopyranosyl - (1 → 4) -α-D グルコピラノシル−(1→}の構造を有する環状四糖などの環状の糖類、エリスリトール、マンニトール、ソルビトール、キシリトール、マルチトール、還元水飴などの糖アルコール類、アスパルテーム、ステビア抽出物、スクラロース、アセスルファムKなどの高甘味度甘味料、プルラン、カラギーナン、コンドロイチン硫酸などのムコ多糖体やその塩類、天然ガム類、キチン、キトサン、カルボキシメチルセルロースをはじめとする合成高分子ポリマー、コラーゲン、ゼラチンなどの増粘剤の何れか1種又は2種以上を添加することができる。なかでも、コンドロイチン硫酸やグルコサミンを併用することにより、本発明の経口摂取用組成物の美肌効果を、より増強することができる。 Glucopyranosyl - (1 →} cyclic saccharides such as cyclotetrasaccharide having a structure of, erythritol, mannitol, sorbitol, xylitol, maltitol, sugar alcohols such as reduced starch syrup, aspartame, stevia extract, sucralose, such as acesulfame K high intensity sweeteners, pullulan, carrageenan, mucopolysaccharides and salts thereof such as chondroitin sulfate, natural gums, chitin, chitosan, synthetic high polymers, including carboxy methyl cellulose, collagen, any thickeners such as gelatin It may be added one or more or. Among these, the combined use of chondroitin sulfate or glucosamine, beautiful skin effect of oral ingestible composition of the present invention can be more enhanced.

また、本発明の経口摂取用組成物には、上記以外にも、例えば、ビタミンB 、ビタミンB 、ビタミンB 、ビタミンB 12 、ビタミンE、ルチン・ヘスペリジン・ナリンジンなどのバイオフラボノイド類或いは、これらビタミンやフラボノイドの誘導体など、アミノ酸類、CoQ10(コエンザイムQ10)、アデノシンやその誘導体、それらのモノフォスフェイト、ジフォスフェイト或いはトリフォスフェイトのような核酸関連物質、プロポリス、フラボノイド類などの成分、海洋深層水などのミネラル類、賦形剤、結合剤、被覆剤、滑沢剤、崩壊剤、増量剤、抗酸化剤、矯味矯臭剤、呈味剤、乳化・可溶化・分散剤、安定剤、pH調節剤、着色料、香料、甘味料、酸味料などから選ばれる何れか1種又は2種以上を含有させる Further, the ingestible compositions of the present invention, in addition to the above, for example, vitamin B 1, vitamin B 2, vitamin B 6, vitamin B 12, vitamin E, bioflavonoids such as rutin, hesperidin, naringin or , ingredients such as those including vitamins or derivatives of flavonoids, amino acids, CoQ10 (coenzyme Q10), adenosine and its derivatives, their mono phosphate, nucleic acid-related substance, propolis, flavonoids such as diphosphate or triforine scan Fate , minerals such as deep sea water, excipients, binding agents, coating agents, lubricants, disintegrants, bulking agents, antioxidants, flavoring agents, Teiajizai, emulsification and solubilizing and dispersing agents, stabilizing agents, pH adjusting agents, colorants, flavors, sweeteners, is contained one kind or two or more species selected from such acidulants とも随意である。 And it is also optional.

本発明の経口摂取用組成物は、ヒアルロン酸及びL−アスコルビン酸類を、該組成物が完成するまでの工程で、或いは、完成品に対して、含有せしめればよく、その具体的な方法としては、例えば、混和、混捏、溶解、融解、分散、懸濁、乳化、浸透、晶出、散布、塗布、付着、噴霧、被覆(コーティング)、注入、浸漬、固化、逆ミセル化などの、飲食品の製造に使用することのできる1種又は2種以上の方法の組み合わせが適宜に選ばれる。 Oral intake composition of the present invention, the hyaluronic acid and L- ascorbic acids, the steps up to the composition is complete, or the finished product may be Seshimere containing, as its specific method It is, for example, mixing, kneading, dissolving, melting, dispersing, suspending, emulsifying, penetrating, crystallization, spray, coating, deposition, spraying, coating (coating), injection, dipping, solidifying, such as reverse micellization, food the combination of one or more methods can be used in the manufacture of goods is chosen appropriately.

本発明の経口摂取用組成物は、その形状を問わず、例えば、液状、シラップ、マスキット、ペースト、粉末、固状、半固状、顆粒、錠剤、ゲルなどの何れの形状であってもよく、そのままで、又は、必要に応じて、増量剤、賦形剤、結合剤などと混合して、液剤、乳剤、懸濁剤、シラップ剤、ペースト、顆粒剤、粉末剤、錠剤、カプセル剤など各種剤型で使用することもできる。 Oral intake composition of the present invention, regardless of its shape, for example, liquid, syrup, massecuite, paste, powder, solid, semi-solid, granules, tablets may be any shape such as a gel , neat or, optionally, extenders, excipients, are mixed with binders and the like, solutions, emulsions, suspensions, syrups, pastes, granules, powders, tablets, capsules, etc. It may be used in various dosage forms.

以下、実験例により本発明をさらに詳細に説明する。 Hereinafter, a more detailed description of the present invention by examples.

<実験例1:ヒアルロン酸及び/又はL−アスコルビン酸類の経口摂取の肌に及ぼす影響> <Experimental Example 1: Effect on the skin of the oral intake of hyaluronic acid and / or L- ascorbic acids>
ヒアルロン酸及び/又はL−アスコルビン酸類の経口摂取の肌に及ぼす影響を調べる試験を以下のように行った。 The test to examine the effects on the skin by ingestion of hyaluronic acid and / or L- ascorbic acids was performed as follows. すなわち、ヒアルロン酸と、L−アスコルビン酸、L−アスコルビン酸2−グルコシド(株式会社林原商事販売、商品名「アスコフレッシュ」)、L−アスコルビン酸脂肪酸エステル、滑潤剤としてショ糖脂肪酸エステル、及び、賦形剤として精製マルトース(株式会社林原商事販売、商品名「サンマルトS」)を、表1に示す質量比で混合して、全量を10質量部として、これを常法により打錠して、各々0.3g/錠の錠剤を調製した。 In other words, a hyaluronic acid, L- ascorbic acid, L- ascorbic acid 2-glucoside (Hayashibara Shoji, trade name "Fiasco fresh"), L- ascorbic acid fatty acid ester, sucrose fatty acid ester as NameraJun agent and,, purification maltose (Hayashibara Shoji, trade name "Sanmaruto S") as excipients, are mixed at a mass ratio shown in Table 1, as 10 parts by mass of the total amount, which was tableted by a conventional method, each was prepared tablets 0.3 g / tablet. その各々の配合の錠剤につき、各々17名の被験者に、1日当たり6錠を、3ヶ月間経口摂取させた。 Per tablet of each formulation, the subject of each 17 people per day 6 tablets were 3 months ingestion. 各々の被験者について、肌の状態を、下記評価方法1乃至評価方法3を用いて評価し、その結果を表1に示す。 For each subject, the skin condition was evaluated using the following evaluation method 1 to evaluate the method 3, and the results are shown in Table 1. なお、L−アスコルビン酸2−グルコシド及びL−アスコルビン酸脂肪酸エステルの配合量は、L−アスコルビン酸に換算した量を表1に示した。 The amount of the L- ascorbic acid 2-glucoside and L- ascorbic acid fatty acid ester, an amount converted to L- ascorbic acid shown in Table 1. なお、陰性対照として、これらの錠剤を摂取しなかった被験者17名についても、同様に評価を行い、その結果を併せて表1に示す。 As a negative control, for the subject 17 people who did not take these tablets evaluated in the same manner are shown in Table 1 together results.
<評価方法1> <Evaluation Method 1>
摂取前、摂取2ヵ月後及び3ヵ月後に頬の角層水分蒸散量をTEWAメーター(テヴァメーター)により測定した。 Before ingestion, the stratum corneum water loss cheek after and after 3 months consumption 2 months were measured by TEWA meter (Teva meter). 配合例毎に被験者17名の頬からの角層水分蒸散量の平均値を求めた。 To obtain an average value of the stratum corneum water loss from the cheeks of the subject 17 people for each Formulation Example.
<評価方法2> <Evaluation Method 2>
各々の被験者を、摂取前及び摂取3ヵ月後に、角層の重層剥離の程度について観察し、摂取前に比してどのような変化が認められたかを、5段階にスコア化した(1:減少した、2:少し減少した、3:変化無し、4:少し増加した、5:増加した)。 Each of the subject after ingestion before and ingestion 3 months, then observed for the degree of layer peeling of the stratum corneum, what changes whether observed was scored in 5 levels than prior to ingestion (1: decrease and, 2: was a little decrease, 3: no change, 4: a little increase, 5: increased). 各配合の錠剤を摂取した17名の被験者ごとにスコアの平均を求めた。 To obtain an average score for each subject 17 people who had ingested tablets of each formulation.
<評価方法3> <Evaluation Method 3>
各々の被験者から、摂取3ヵ月後に肌のかさつきの程度と、肌の弛み、シワ及びコジワの変化についてのアンケート調査を行った。 From each of the subject, and the degree of dry skin after ingestion three months, skin loose, a questionnaire survey was conducted for the change of wrinkles and fine lines. それぞれの項目に関して改善を自覚した者の割合を改善率とした。 And the proportion of those who were aware of the improvement for each of the items and the improvement rate.

<結果> <Result>
表1から明らかなよう、ヒアルロン酸或いはL−アスコルビン酸類を単独で摂取した場合(配合No.1乃至配合No.4)には、頬からの水分蒸散量、角層の重層剥離の程度、肌のかさつきの程度、肌の弛み、シワ及びコジワを改善の程度の何れにおいても、摂取前に比して変化は認められなかった。 As apparent from Table 1, when it is taken alone hyaluronic acid or L- ascorbic acid (formulation No.1 to blend No.4), the extent of overlay separation of water loss, the stratum corneum of the cheek, the skin loosening of the extent of bulk with, the skin, in any of the degree of improvement of wrinkles and fine lines also vary compared to before ingestion was observed. これに対して、ヒアルロン酸とL−アスコルビン酸類を等質量配合した錠剤を摂取した場合(配合No.5乃至配合No.7)には、評価に使用した何れの項目においても、摂取前に比して改善が認められた。 In contrast, when it is ingested tablets equal mass Hyaluronic acid and L- ascorbic acid (blend No.5 to blend No.7), in any of the items used for the evaluation, the ratio prior to ingestion improvement and was observed. また、ヒアルロン酸と組み合わせるL−アスコルビン酸類としては、L−アスコルビン酸2−グルコシドを使用した場合に最も強い改善効果が認められた。 As the L- ascorbic acid combined with hyaluronic acid, the strongest improvement when using L- ascorbic acid 2-glucoside was found.

<実験例2:ヒアルロン酸及びL−アスコルビン酸類の摂取量の及ぼす肌への影響> <Experimental Example 2: Effect of the skin on the intake of hyaluronic acid and L- ascorbic acids>
ヒアルロン酸及びL−アスコルビン酸類の摂取量の及ぼす肌への影響を調べる実験を以下のようにして行った。 An experiment to investigate the effect of the skin on the intake of hyaluronic acid and L- ascorbic acids was carried out in the following manner. 即ち、実験例1で調製した配合No. That is, blending was prepared in Experimental Example 1 No. 6のヒアルロン酸とL−アスコルビン酸2−グルコシドとを等質量配合した錠剤を使用して、1日当たり、1錠、2錠、3錠、4錠、5錠、或いは6錠の何れかを、各々17名の被験者に2ヶ月間摂取させた。 Use tablets equal mass blended 6 and hyaluronic acid and L- ascorbic acid 2-glucoside, per day, one tablet, 2 tablets, 3 tablets, 4 tablets, 5 tablets, or 6 tablets one, It was two months intake in each 17 subjects. 各々の被験者について、実験終了時の、被験者の頬の皮膚の状態を、実験例1と同じ評価方法1乃至評価方法3を用いて評価し、その結果を表2に示す。 For each subject, at the end of the experiment, the skin condition of the subject's cheek, and evaluated using the same evaluation method 1 to evaluate the method 3 as in Experimental Example 1. The results are shown in Table 2. なお、実験例2と実験例1とは、被験者が重複しないように実験を行った。 Note that in Experimental Example 2 and Experimental Example 1, an experiment was conducted so that the subject does not overlap.

表2から明らかなように、錠剤を1日当たり1錠摂取した場合には、評価に使用した何れの項目においても、摂取前に比して改善は認められなかった。 As apparent from Table 2, when taken tablets per day tablet is in any of the items used for the evaluation, improvement compared to before ingestion was observed. これに対して、1日当たり、2錠を摂取した場合には、評価に使用した何れの項目においても、摂取前に比して改善が認められ、その改善は、1日当たり3錠以上の摂取で顕著であった。 In contrast, 1 day, when taken 2 tablets can, in any of the items used for the evaluation, improvement compared to prior to ingestion was observed, the improvement, at day 3 tablets over ingestion It was remarkable.

<実験例3:経口摂取用組成物中のヒアルロン酸とL−アスコルビン酸類との配合割合の肌に及ぼす影響> <Experimental Example 3: Effect on skin mixing ratio of hyaluronic acid and L- ascorbic acids ingestible composition>
実験例1で、ヒアルロン酸とL−アスコルビン酸類とを組み合わせて経口摂取することにより、肌の弛み、シワ及びコジワが改善されることが確認されたので、経口摂取用組成物中のヒアルロン酸とL−アスコルビン酸類との配合割合の肌に及ぼす影響を調べる試験を以下のように行った。 In Experimental Example 1, by oral ingestion in combination with hyaluronic acid and L- ascorbic acids, skin slackness of, so that the wrinkles and fine lines is improved has been confirmed, and hyaluronic acid for oral ingestion composition the test to examine the effects on skin blending ratio of the L- ascorbic acids was performed as follows. すなわち、ヒアルロン酸と、L−アスコルビン酸2−グルコシド(株式会社林原商事販売、商品名「アスコフレッシュ」)、ショ糖脂肪酸エステル、賦形剤として精製マルトース(株式会社林原商事販売、商品名「サンマルトS」)を表3に示す質量比で混合して、全量を10質量部とし、これを常法により打錠して、各々0.3g/錠の錠剤を調製した。 In other words, a hyaluronic acid, L- ascorbic acid 2-glucoside (Hayashibara Shoji, trade name "Fiasco fresh"), sucrose fatty acid ester, purified maltose (Hayashibara Shoji as an excipient, trade name "Sanmaruto the S ") were mixed at a mass ratio shown in Table 3, and 10 parts by mass of the total amount, which was tableted by a conventional method were respectively prepared tablets 0.3 g / tablet. その各々の配合につき、各々17名の被験者に、1日当たり6錠、3ヶ月間経口摂取させた。 Per each of the formulations, to the subject of each 17 people, 1 day 6 tablets was three months oral ingestion. 各々の被験者について、実験終了時の被験者の肌の状態を、実験例1と同じ評価方法1乃至評価方法3を用いて評価し、その結果を表3に示す。 For each subject, the skin condition of the subjects at the end of the experiment, were evaluated using the same evaluation method 1 to evaluate the method 3 as in Experimental Example 1. The results are shown in Table 3. なお、L−アスコルビン酸2−グルコシドの配合量は、L−アスコルビン酸に換算した量を表3に示した。 The amount of the L- ascorbic acid 2-glucoside, an amount converted to L- ascorbic acid shown in Table 3. なお、実験例3と、実験例1、実験例2とは、何れも被験者が重複しないように実験を行った。 Incidentally, as in Experimental Example 3, Example 1, and the experimental example 2, both experiments were conducted as subjects do not overlap.

表3から明らかなように、ヒアルロン酸とL−アスコルビン酸を、質量比で1:4乃至4:1(配合No.3乃至配合No.9)の割合で、とりわけ1:2乃至2:1の割合で配合した錠剤を摂取した場合(配合No.5乃至配合No.7)には、評価に使用した角質の水分蒸散量、角層の重層剥離の程度、肌のかさつきの程度、肌の弛み、シワ及びコジワの改善の何れの項目においても、改善が認められた。 As apparent from Table 3, the hyaluronic acid and L- ascorbic acid, at a mass ratio of 1: 4 to 4: 1 ratio (compounding No.3 to formulation No.9), especially 1: 2 to 2: 1 the case of ingestion of tablets in a proportion of (formulation No.5 to blend No.7), water loss of keratin used in the evaluation, the extent of overlay peeling of the stratum corneum, the degree of skin umbrella with, skin slack, in any of the items of improvement of wrinkles and fine lines, showed improvement. これに対して、ヒアルロン酸とL−アスコルビン酸を、0.1:1.9(配合No.1)、0.2:1.8(配合No.2)、1.8:0.2(配合No.10)、或いは、1.9:0.1(配合No.11)の配合割合としたものでは、肌の弛み、シワ及びコジワについては、何れも摂取前に比して改善は認められなかった。 In contrast, hyaluronic acid and L- ascorbic acid, 0.1: 1.9 (Formulation No.1), 0.2: 1.8 (Formulation No.2), 1.8: 0.2 ( formulation No.10), or 1.9: 0.1 (by way was mixing ratio of formulation No.11), skin slackness of, for wrinkles and fine lines, both observed improved compared to before ingestion It is did not.

これらの実験結果は、ヒアルロン酸とL−アスコルビン酸に換算したときのL−アスコルビン酸類とを、質量比で1:4乃至4:1の割合で、さらに望ましくは1:2乃至2:1の割合で配合した経口摂取用組成物が、肌の弛み、シワ及びコジワを改善し、潤いのある肌とする、優れた美肌作用を有していることを物語っている。 These experimental results, and L- ascorbic acid when converted into hyaluronic acid and L- ascorbic acid, at a mass ratio of 1: 4 to 4: 1 ratio, more preferably 1: 2 to 2: 1 oral intake composition blended with ratio, slack skin, improving wrinkles and fine lines, and skin moist testifies that it has an excellent skin-beautifying action.

以下、実施例により本発明をさらに詳細に説明するが、本発明はこれら実施例に何ら限定されるものではない。 Hereinafter, a more detailed description of the present invention through examples, the present invention is not intended to be limited to these examples.

<美肌用の経口摂取用組成物> <Oral intake composition for beautiful skin>
精製マルトース(株式会社林原商事販売、 Purified maltose (Hayashibara Shoji,
商品名「サンマルトS」) 63.5質量部 含水結晶α,α−トレハロース(株式会社 林原商事販売、商品名「トレハ」) 25質量部 滑沢剤 5質量部 牡蠣殻カルシウム 2質量部 ヒアルロン酸 2質量部 L−アスコルビン酸2−グルコシド(株式会社 林原商事販売、商品名「アスコフレッシユ」) 1質量部 糖転移ルチン(東洋精糖株式会社販売、商品名 「αGルチンP」) 0.5質量部 酸味料(有機酸類) 適 量 レモン及びライムのフレーバー 適 量 全量を100質量部とし、これらの成分を均質になるまで攪拌混合し、常法により、0.5gずつ打錠して、錠剤を調製した。 Trade name "Sanmaruto S") 63.5 parts by weight of hydrous crystalline alpha, alpha-trehalose (Hayashibara Shoji, trade name "TREHA") 25 parts by weight lubricant 5 parts by oyster shell calcium parts by hyaluronic acid 2 parts by weight of L- ascorbic acid 2-glucoside (Hayashibara Shoji, trade name "Asukofuresshiyu") one part by weight of glycosyltransferase rutin (Toyo sugar Refining Co., Ltd. sold under the trade name "αG rutin P") 0.5 parts by weight acidulants (organic acids) q.s. lemon and lime flavors q.s. total amount to 100 parts by weight, followed by stirring and mixing to homogeneity of these ingredients, by a conventional method and tableted by 0.5g, prepare tablets did.

本品は、肌の弛み、シワ及び/又はコジワを改善することができる。 The product, skin sagging, it is possible to improve wrinkles and / or fine lines. また、本品は、角層のバリア機能を改善し、皮膚の保水力を高め、肌荒れの改善し、肌のうるおいの向上することができる。 The product improves the barrier function of the stratum corneum, increases the water-holding capacity of the skin, can improve skin roughness, improving the skin moisture. 本品はこれらの作用効果を標榜して、美肌用の健康補助食品として販売することもできる。 This product is advocating these actions and effects, it can also be sold as a health supplement for beautiful skin.

<美肌用の経口摂取用組成物> <Oral intake composition for beautiful skin>
粉末マルチトール 500質量部 アスコルビン酸2−グルコシド(株式会社 林原商事販売、商品名「アスコフレッシユ」) 50質量部 ヒアルロン酸 25質量部 粉末卵黄 190質量部 脱脂粉乳 200質量部 塩化ナトリウム 4.4質量部 塩化カリウム 1.85質量部 硫酸マグネシウム 4質量部 コンドロイチン硫酸 0.1質量部 グルコサミン 0.5質量部 チアミン 0.01質量部 ビタミンEアセテート 0.6質量部 ニコチン酸アミド 0.04質量部 コエンザイムQ10 0.03質量部 糖転移ヘスペリジン(東洋精糖株式会社販売、 Powder maltitol 500 parts by weight of ascorbic acid 2-glucoside (commercialized by Hayashibara Shoji Inc., product name "Asukofuresshiyu") 50 parts by weight of hyaluronic acid 25 parts powder yolk 190 parts by skim milk powder 200 parts by weight of sodium chloride 4.4 mass parts potassium chloride 1.85 parts by mass of magnesium 4 parts by weight chondroitin sulfate 0.1 parts by glucosamine 0.5 parts of thiamine 0.01 part by weight of vitamin E acetate 0.6 part by weight of nicotinamide acid 0.04 parts by weight coenzyme Q10 0.03 parts by weight of sugar transition hesperidin (Toyo sugar Refining Co., Ltd. sales,
商品名「αGヘスペリジンPS」) 0.02質量部上記配合組成からなる配合物を調製した。 Trade name "αG hesperidin PS") 0.02 parts by mass formulation consisting of the blend composition was prepared. この配合物25質量部を精製水150質量部に均一に分散・溶解させ、200gずつ褐色ガラス瓶に封入した。 The formulation 25 parts by weight evenly dispersed and dissolved in purified water 150 parts by mass, sealed in a brown glass bottle by 200 g.

本品は、肌の弛み、シワ及び/又はコジワを改善することができる。 The product, skin sagging, it is possible to improve wrinkles and / or fine lines. また、本品は、角層のバリア機能を改善し、皮膚の保水力を高め、肌荒れの改善し、肌のうるおいの向上することができる。 The product improves the barrier function of the stratum corneum, increases the water-holding capacity of the skin, can improve skin roughness, improving the skin moisture. 本品はこれらの作用効果を標榜して、美肌用の健康補助食品として販売することもできる。 This product is advocating these actions and effects, it can also be sold as a health supplement for beautiful skin. なお、本品は、ヒトのみならず、家畜、ペットなどの動物のための経口摂取又は、胃や腸へゾンデ等を使用して直接投与する経管投与用の組成物としても有利に利用できる。 The present product is not only human, domestic animals, ingestion or for animals, such as pets, it may be advantageously utilized as a composition for gavage administered directly using sonde like the stomach and intestines . また、本品は糖転移ヘスペリジンを含んでいるので、血中脂質や血中コレステロールなどの、血中脂質の低減のために用いられる旨を標榜することも随意である。 The product is because it contains a glycosyl hesperidin, such as blood lipids and blood cholesterol can be arbitrarily advocating that used for reducing blood lipid.

<美肌用の経口摂取用組成物> <Oral intake composition for beautiful skin>
粉末マルチトール 25質量部 含水結晶α,α−トレハロース(株式会社林原商事 販売、商品名「トレハ」) 54質量部 滑沢剤 3質量部 L−アスコルビン酸2−グルコシド(株式会社 林原商事販売、商品名「アスコフレッシユ」) 10質量部 グルコサミン 2.5質量部 コンドロイチン硫酸ナトリウム 1.5質量部 ヒアルロン酸 4質量部上記配合処方に基づき、これらの成分を均質になるまで攪拌混合し、常法により、0.5gずつ打錠して、錠剤を調製した。 Powder maltitol 25 parts by weight of hydrous crystalline alpha, alpha-trehalose (Hayashibara Shoji, trade name "TREHA") 54 parts by weight lubricants 3 parts by L- ascorbic acid 2-glucoside (commercialized by Hayashibara Shoji Inc., product based on the name "Asukofuresshiyu") 10 parts by glucosamine 2.5 parts by weight sodium chondroitin sulfate 1.5 parts by weight of hyaluronic acid 4 parts by mass the above formulation was stirred and mixed until homogeneous these components, by a conventional method , and tableted by 0.5g, tablets were prepared.

本品は、肌の弛み、シワ及び/又はコジワを改善することができる。 The product, skin sagging, it is possible to improve wrinkles and / or fine lines. また、本品は、角層のバリア機能を改善し、皮膚の保水力を高め、肌荒れの改善し、肌のうるおいの向上することができる。 The product improves the barrier function of the stratum corneum, increases the water-holding capacity of the skin, can improve skin roughness, improving the skin moisture. 本品はこれらの作用効果を標榜して、美肌用の健康補助食品として販売することもできる。 This product is advocating these actions and effects, it can also be sold as a health supplement for beautiful skin.

本発明の経口摂取用組成物を摂取することにより、肌の弛み、シワ及び/又はコジワを改善することができるだけでなく、肌のバリア機能を高め、肌の保水力を高めることができるので、肌を美しく保つことができる。 By ingesting an oral ingestible composition of the present invention, skin slackness of, not only can improve wrinkles and / or fine lines, enhance the skin barrier function, it is possible to enhance the water-holding capacity of the skin, skin can be kept beautiful. 本発明は、斯くも顕著な作用効果を奏する発明であり、斯界に多大の貢献をする、誠に意義のある発明である。 The present invention is an invention which thus also exhibits the remarkable action and effect, the great contribution to the art, it is indeed meaningful invention.

Claims (5)

  1. ヒアルロン酸とL−アスコルビン酸に換算したときのL−アスコルビン酸類との配合割合が、質量比で1:4乃至4:1であることを特徴とする美肌用の経口摂取用組成物。 Blending ratio of the L- ascorbic acid when converted into hyaluronic acid and L- ascorbic acid, 1 weight ratio: 4 to 4: orally ingestible composition for beautiful skin, which is a 1.
  2. さらに、コンドロイチン硫酸及び/又はグルコサミンを含有することを特徴とする請求項1記載の美肌用の経口摂取用組成物。 Further, ingestible composition for beautiful skin according to claim 1, characterized by containing the chondroitin sulfate and / or glucosamine.
  3. L−アスコルビン酸類が、L−アスコルビン酸2−グルコシドであることを特徴とする請求項1又は2記載の美肌用の経口摂取用組成物。 L- ascorbic acids, according to claim 1 or 2 skin-beautifying ingestible composition for according to characterized in that the L- ascorbic acid 2-glucoside.
  4. 美肌作用を有することを標榜してなる請求項1乃至3の何れかに記載の美肌用の経口摂取用組成物。 Oral intake composition for beautiful skin according to any one of claims 1 to 3 comprising advocated to have beautiful skin effect.
  5. 肌の弛み、シワ及び/又はコジワの改善剤・抑制剤としての請求項1乃至4の何れかに記載の美肌用の経口摂取用組成物。 Skin slackness of wrinkles and / or claims 1 to ingestible compositions for beautiful skin according to any one of 4 as improving agents, inhibitors of fine lines.
JP2005250453A 2005-08-31 2005-08-31 Oral intake composition for beautiful skin Active JP4982718B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005250453A JP4982718B2 (en) 2005-08-31 2005-08-31 Oral intake composition for beautiful skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005250453A JP4982718B2 (en) 2005-08-31 2005-08-31 Oral intake composition for beautiful skin

Publications (2)

Publication Number Publication Date
JP2007063177A true JP2007063177A (en) 2007-03-15
JP4982718B2 JP4982718B2 (en) 2012-07-25

Family

ID=37925769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005250453A Active JP4982718B2 (en) 2005-08-31 2005-08-31 Oral intake composition for beautiful skin

Country Status (1)

Country Link
JP (1) JP4982718B2 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009116491A1 (en) 2008-03-21 2009-09-24 株式会社林原生物化学研究所 Monoclonal antibody specifically recognizing human interferon alpha subtype alpha-8 and mutant protein thereof
EP2301944A1 (en) 2009-09-03 2011-03-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Particulate composition containing anhydrous crystalline 2-O-alpha -D-glucosyl-L-ascorbic acid, process for producing the same, and uses thereof
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
WO2012033218A1 (en) 2010-09-07 2012-03-15 株式会社林原生物化学研究所 HYDROUS CRYSTALS OF 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID, POWDER CONTAINING HYDROUS CRYSTALS OF 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID, METHOD FOR PRODUCING THE HYDROUS CRYSTALS, METHOD FOR PRODUCING THE POWDER, USE OF THE HYDROUS CRYSTALS, AND USE OF THE POWDER
WO2012121297A1 (en) 2011-03-07 2012-09-13 株式会社林原 METHOD FOR PRODUCING 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID ANHYDROUS CRYSTAL-CONTAINING POWDER
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US8338388B2 (en) 2003-04-10 2012-12-25 Allergan, Inc. Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US8338375B2 (en) 2007-05-23 2012-12-25 Allergan, Inc. Packaged product
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
US8394783B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8586562B2 (en) 2010-03-12 2013-11-19 Allergan Industrie, Sas Fluid compositions for improving skin conditions
US8691279B2 (en) 2010-03-22 2014-04-08 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8946192B2 (en) 2010-01-13 2015-02-03 Allergan, Inc. Heat stable hyaluronic acid compositions for dermatological use
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US9228027B2 (en) 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9265761B2 (en) 2007-11-16 2016-02-23 Allergan, Inc. Compositions and methods for treating purpura
US9284359B2 (en) 2011-01-19 2016-03-15 Hirosaki University Method for mass preparation of proteoglycan
JP2016069286A (en) * 2014-09-26 2016-05-09 株式会社ファンケル L-ascorbic acid sustained-release formulation
JP5933264B2 (en) * 2009-07-16 2016-06-08 サンスター株式会社 Proteoglycan-containing material
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9795711B2 (en) 2011-09-06 2017-10-24 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967262A (en) * 1995-08-31 1997-03-11 Shiseido Co Ltd Skin activator and skin activating food
JP2002223726A (en) * 2001-01-31 2002-08-13 Ribateepu Seiyaku Kk Food for beauty
JP2003095961A (en) * 2001-09-27 2003-04-03 Combi Corp Skin beautifying promoter
JP2004250372A (en) * 2003-02-20 2004-09-09 Fancl Corp Skin aging inhibitor/improver and/or rough skin inhibitor/improver kit
JP2006265287A (en) * 2005-03-22 2006-10-05 Q P Corp Low molecular weight hyaluronic acid and/or its salt, its manufacturing process and cosmetic and food composition containing it
JP2007043960A (en) * 2005-08-10 2007-02-22 Towa Kagaku Kk Energy-promoting/aging-preventing jellied food and method for producing the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967262A (en) * 1995-08-31 1997-03-11 Shiseido Co Ltd Skin activator and skin activating food
JP2002223726A (en) * 2001-01-31 2002-08-13 Ribateepu Seiyaku Kk Food for beauty
JP2003095961A (en) * 2001-09-27 2003-04-03 Combi Corp Skin beautifying promoter
JP2004250372A (en) * 2003-02-20 2004-09-09 Fancl Corp Skin aging inhibitor/improver and/or rough skin inhibitor/improver kit
JP2006265287A (en) * 2005-03-22 2006-10-05 Q P Corp Low molecular weight hyaluronic acid and/or its salt, its manufacturing process and cosmetic and food composition containing it
JP2007043960A (en) * 2005-08-10 2007-02-22 Towa Kagaku Kk Energy-promoting/aging-preventing jellied food and method for producing the same

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10080767B2 (en) 2003-04-10 2018-09-25 Allergan Industrie Sas Injectable monophase hydrogels
US8563532B2 (en) 2003-04-10 2013-10-22 Allergan Industrie Sas Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US9062130B2 (en) 2003-04-10 2015-06-23 Allergan Industrie Sas Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US8338388B2 (en) 2003-04-10 2012-12-25 Allergan, Inc. Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US8338375B2 (en) 2007-05-23 2012-12-25 Allergan, Inc. Packaged product
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
US8703118B2 (en) 2007-10-09 2014-04-22 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
US9265761B2 (en) 2007-11-16 2016-02-23 Allergan, Inc. Compositions and methods for treating purpura
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8513216B2 (en) 2007-11-30 2013-08-20 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8394783B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8853184B2 (en) 2007-11-30 2014-10-07 Allergan, Inc. Polysaccharide gel formulation having increased longevity
WO2009116491A1 (en) 2008-03-21 2009-09-24 株式会社林原生物化学研究所 Monoclonal antibody specifically recognizing human interferon alpha subtype alpha-8 and mutant protein thereof
US8357782B2 (en) 2008-03-21 2013-01-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Monoclonal antibodies specific for human interferon-alpha subtype alpha 8
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
US9089517B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9089518B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9238013B2 (en) 2008-08-04 2016-01-19 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US9358322B2 (en) 2008-08-04 2016-06-07 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US10328180B2 (en) 2008-08-04 2019-06-25 Allergan Industrie, S.A.S. Hyaluronic acid-based gels including lidocaine
US8822676B2 (en) 2008-08-04 2014-09-02 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US9089519B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9228027B2 (en) 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9861570B2 (en) 2008-09-02 2018-01-09 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9585828B2 (en) 2009-07-16 2017-03-07 Sunstar Inc. Proteoglycan-containing material
JP5933264B2 (en) * 2009-07-16 2016-06-08 サンスター株式会社 Proteoglycan-containing material
US9265781B2 (en) 2009-09-03 2016-02-23 Hayashibara Co., Ltd. Process for producing a particulate composition comprising anhydrous crystalline 2-O-alpha-D-glucosyl-L-ascorbic acid
US8765416B2 (en) 2009-09-03 2014-07-01 Hayashibara Co., Ltd. Particulate composition containing anhydrous crystalline 2-O-alpha-D-glucosyl-L-ascorbic acid, process for producing the same, and uses thereof
EP3081573A1 (en) 2009-09-03 2016-10-19 Hayashibara Co., Ltd. Particulate composition containing anhydrous crystalline 2-o-alpha -d-glucosyl-l-ascorbic acid, process for producing the same, and uses thereof
US9186368B2 (en) 2009-09-03 2015-11-17 Hayashibara Co., Ltd. Process for producing a particulate composition comprising an hydrous crystalline 2-O-α-D-glucosyl-L-ascorbic acid
EP2743276A1 (en) 2009-09-03 2014-06-18 Hayashibara Co., Ltd. Particulate composition containing anhydrous crystalline 2-O-alpha -D-glucosyl-L-ascorbic acid, process for producing the same, and uses thereof
US9872872B2 (en) 2009-09-03 2018-01-23 Hayashibara Co., Ltd. Process for producing a particulate composition comprising an hydrous crystalline 2-O-α-D-glucosyl-L-ascorbic acid
EP2301944A1 (en) 2009-09-03 2011-03-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Particulate composition containing anhydrous crystalline 2-O-alpha -D-glucosyl-L-ascorbic acid, process for producing the same, and uses thereof
US8946192B2 (en) 2010-01-13 2015-02-03 Allergan, Inc. Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20120225842A1 (en) * 2010-01-13 2012-09-06 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US9333160B2 (en) 2010-01-13 2016-05-10 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US9855367B2 (en) 2010-01-13 2018-01-02 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US9655991B2 (en) 2010-01-13 2017-05-23 Allergan Industrie, S.A.S. Stable hydrogel compositions including additives
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US9125840B2 (en) 2010-03-12 2015-09-08 Allergan Industrie Sas Methods for improving skin conditions
US8586562B2 (en) 2010-03-12 2013-11-19 Allergan Industrie, Sas Fluid compositions for improving skin conditions
US9585821B2 (en) 2010-03-12 2017-03-07 Allergan Industrie Sas Methods for making compositions for improving skin conditions
US8921338B2 (en) 2010-03-12 2014-12-30 Allergan Industrie, Sas Fluid compositions for improving skin conditions
US8691279B2 (en) 2010-03-22 2014-04-08 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US9480775B2 (en) 2010-03-22 2016-11-01 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US9012517B2 (en) 2010-03-22 2015-04-21 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US10111984B2 (en) 2010-03-22 2018-10-30 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
WO2012033218A1 (en) 2010-09-07 2012-03-15 株式会社林原生物化学研究所 HYDROUS CRYSTALS OF 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID, POWDER CONTAINING HYDROUS CRYSTALS OF 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID, METHOD FOR PRODUCING THE HYDROUS CRYSTALS, METHOD FOR PRODUCING THE POWDER, USE OF THE HYDROUS CRYSTALS, AND USE OF THE POWDER
US9284359B2 (en) 2011-01-19 2016-03-15 Hirosaki University Method for mass preparation of proteoglycan
KR20140039177A (en) 2011-03-07 2014-04-01 가부시기가이샤하야시바라 Method for producing 2-o-a-d-glucosyl-l-ascorbic acid anhydrous crystal-containing powder
WO2012121297A1 (en) 2011-03-07 2012-09-13 株式会社林原 METHOD FOR PRODUCING 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID ANHYDROUS CRYSTAL-CONTAINING POWDER
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9737633B2 (en) 2011-06-03 2017-08-22 Allergan, Inc. Dermal filler compositions including antioxidants
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US9950092B2 (en) 2011-06-03 2018-04-24 Allergan, Inc. Dermal filler compositions for fine line treatment
US9962464B2 (en) 2011-06-03 2018-05-08 Allergan, Inc. Dermal filler compositions including antioxidants
US9795711B2 (en) 2011-09-06 2017-10-24 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9821086B2 (en) 2011-09-06 2017-11-21 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
JP2016069286A (en) * 2014-09-26 2016-05-09 株式会社ファンケル L-ascorbic acid sustained-release formulation

Also Published As

Publication number Publication date
JP4982718B2 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
JP5270058B2 (en) Trophic improved inulin products
JP2874967B2 (en) Agent aqueous suspension for insoluble pharmaceutically active substance in the essentially water
WO2009104696A1 (en) Oral or enteral composition useful for recovery of physical functions
KR100592690B1 (en) Skin care agent, and health and beauty care food
US8349365B2 (en) Cellooligosaccharide-containing composition
KR100890492B1 (en) Collagen-production enhancer, its preparation and uses
US20090110671A1 (en) Agent for enhanching the production of collagen and it&#39;s use
ES2260293T3 (en) Composition comprising hydroxycitric acid and garcinol for weight reduction.
JP4754066B2 (en) Anti-joint disorder agent
JPH05320052A (en) Nucleic acid ingredient composition
CN1863526B (en) Collagen productin enhancer and production process and use thereof
JP2002529489A (en) Flavor blend in order to hide the unpleasant taste of zinc compounds
JP2001527518A (en) Suppression of undesirable taste of oral compositions
JP4842824B2 (en) Coenzyme q10-containing composition
WO2005023021A1 (en) Diet food
EP3081215A1 (en) Compositions and methods for the sustained release of beta-alanine
WO2006035900A1 (en) Coenzyme q10-containing emulsified composition
JP2001008666A (en) Composition for replenishing oligosaccharide
US9687555B2 (en) Palatable nutritional composition comprising a nucleotide and/or a nucleoside and a taste masking agent
US20100034757A1 (en) Extract powder of indigo plant, and its preparation and uses
EP0382355B1 (en) Growth promoting agent for bacteria containing pullulan with or without dextran
US7994155B2 (en) Accelerator for mineral absorption and use thereof
ES2604700T3 (en) cariostatic material and non-cariogenic agent containing D-sorbose
JP4403182B2 (en) Orally disintegrating n- acetylglucosamine tablet and a manufacturing method thereof
JPH05163160A (en) Nutrient preparation for prevention and treatment of infectious disease caused by immune depression

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110920

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120313

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20120327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120327

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150511

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250